[go: up one dir, main page]

MX2017014666A - Metodos de inmunización contra clostridium difficile. - Google Patents

Metodos de inmunización contra clostridium difficile.

Info

Publication number
MX2017014666A
MX2017014666A MX2017014666A MX2017014666A MX2017014666A MX 2017014666 A MX2017014666 A MX 2017014666A MX 2017014666 A MX2017014666 A MX 2017014666A MX 2017014666 A MX2017014666 A MX 2017014666A MX 2017014666 A MX2017014666 A MX 2017014666A
Authority
MX
Mexico
Prior art keywords
difficile
methods
cdt
purified
toxin
Prior art date
Application number
MX2017014666A
Other languages
English (en)
Inventor
Quemeneur Laurence
J Pietrobon Patricia
LONDONO-HAYES Patricia
HAUSER Steven
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MX2017014666A publication Critical patent/MX2017014666A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La descripción se relaciona generalmente al campo de vacunación terapéutica y/o protectora contra Clostridium difficile (C. difficile). Más específicamente, se relaciona a métodos para inmunizar un hospedero contra cepas C. difficile que expresan toxina binaria C. difficile (CDT) y cepas que no expresan CDT. Estos métodos involucran la administración a un hospedero de una composición inmunogénica que comprende Toxina A C. difficile purificada inactivada y Toxina B purificada. Las toxinas C. difficile purificadas se pueden derivar de una cepa C. difficile que no expresa CDT.
MX2017014666A 2015-05-15 2016-05-14 Metodos de inmunización contra clostridium difficile. MX2017014666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562162357P 2015-05-15 2015-05-15
PCT/US2016/032568 WO2016187073A1 (en) 2015-05-15 2016-05-14 Methods for immunizing against clostridium difficile

Publications (1)

Publication Number Publication Date
MX2017014666A true MX2017014666A (es) 2018-02-09

Family

ID=56101790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014666A MX2017014666A (es) 2015-05-15 2016-05-14 Metodos de inmunización contra clostridium difficile.

Country Status (11)

Country Link
US (1) US20180110849A1 (es)
EP (1) EP3294330A1 (es)
JP (1) JP2018521967A (es)
KR (1) KR20180011784A (es)
CN (1) CN107847576A (es)
AU (1) AU2016263203A1 (es)
BR (1) BR112017024443A2 (es)
CA (1) CA2986025A1 (es)
IL (1) IL255592A (es)
MX (1) MX2017014666A (es)
WO (1) WO2016187073A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018383764A1 (en) * 2017-12-13 2020-07-02 Texas Tech University System Pheromone compositions for stimulating early onset of estrus and reducing labor needs in breeding peri-pubertal suids and methods of use
CN113329766A (zh) * 2018-11-16 2021-08-31 马特里瓦克斯公司 艰难梭菌多组分疫苗
USD1070876S1 (en) 2022-07-14 2025-04-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with transitional graphical user interface

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
MX2010001054A (es) 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
BRPI0816790A8 (pt) 2007-09-14 2017-05-16 Sanofi Pasteur Biologics Co Composições farmacêuticas contendo toxóides a e b de clostridium difficile
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
SG11201507608PA (en) * 2013-03-15 2015-10-29 Sanofi Pasteur Inc Toxoid, compositions and related methods

Also Published As

Publication number Publication date
IL255592A (en) 2018-01-31
JP2018521967A (ja) 2018-08-09
US20180110849A1 (en) 2018-04-26
KR20180011784A (ko) 2018-02-02
EP3294330A1 (en) 2018-03-21
CN107847576A (zh) 2018-03-27
AU2016263203A1 (en) 2017-11-30
BR112017024443A2 (pt) 2018-10-23
CA2986025A1 (en) 2016-11-24
WO2016187073A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
MX351074B (es) Vacunas contra clostridium difficile que comprenden toxinas recombinantes.
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
EP4344741A3 (en) Aav vectors targeted to the central nervous system
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
JO3600B1 (ar) لقاحات مؤتلفة ل fmdv و استخداماتها
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2016009072A (es) Fusion de antigenos micobacterianos heterooligomericos.
MX2016011537A (es) Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
MY191539A (en) Streptococcal vaccine
MX2021013109A (es) Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
WO2019028396A8 (en) Induction of protective immunity against antigens
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
PH12021551816A1 (en) Inactivated apxia, apxiia and apxiiia toxins
MX2019011026A (es) Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer.
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2017014666A (es) Metodos de inmunización contra clostridium difficile.
PH12017501795A1 (en) Pestivirus vaccines for congenital tremors
PH12017500419B1 (en) Recoded arbovirus and vaccines
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
TW201613952A (en) Cdca1-derived peptide and vaccine containing same